Table 1 Demographic and clinical features

32 years (17–60)

18 years (3–46)

 Female

n: 32

49.2%

 Male

n: 33

50.8%

Duration of use

n: 65 (100%)

7 month (3–30)

 Anakinra

n: 41 (63.1%)

6 month (3–30)

 Canakinumab

n: 24 (39.6%)

8 month (3–25)

 Fever

n: 60

92.5%

 Peritonitis

n: 61

93.8%

 Erysipales LE

n: 18

27.7%

 Amlyloidosis

n: 15

23.1%

 Arthritis

n: 11

16.9%

 Pleuritis

n: 20

30.8%

 AxSpa

n: 9

13.8%

 Renal trans

n: 7

10.8%

 M694 V homozygous

n: 29

44.6%

 M694 V heterozygous

n: 8

12.3%

 M680I homozygous

n: 4

6.2%

 E148Q homozygous

n: 1

1.5%

 Compound

n: 16

24.6%

 No

n: 3

4.6%

 R761H heterozygous

n: 1

1.5%

 Others

n: 3

4.6%

 Colchicine-Intolerant

n: 8

12.3%

 Colchicine-Resistant

n: 46

70.8%

 Proteinuria

n: 15

23.1%